OptiVol succeeds in trial, but Medtronic cannot REVERSE CRT findings
This article was originally published in Clinica
Executive Summary
Two trials examining the use of cardiac resynchronisation therapy (CRT) in heart failure patients have resulted in both good and bad news for medtech giant Medtronic.